CorMedix, Inc.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its flagship product, Defencath, is designed to prevent catheter-related bloodstream infections, particularly in patients undergoing hemodialysis. The company aims to address a significant medical need, as infections related to catheters pose severe health risks and can result in substantial healthcare costs. CorMedix's efforts concentrate on enhancing patient safety and improving outcomes in hospital and healthcare settings. With ongoing developments and clinical trials, the company plays a crucial role in the pharmaceutical and medical technology sectors, striving to advance novel solutions that cater to the demands of infection prevention and patient care. Marking its presence in the competitive biopharmaceutical market, CorMedix continues to seek regulatory approvals and partnerships to expand the reach and application of its innovative products.